Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
It is anticipated that following the current period of Covid-19 lockdown, there will be an ongoing requirement for social distancing. The Faculty of Sexual and Reproductive Healthcare (FSRH) makes recommendations relating to contraceptive services at times when lockdown restrictions are eased.
Interim results as of 24 April 2020
An example contraception contingency plan for SRH services.
This document provides guidance on incorrect use of: combined oral contraceptive pills, the combined vaginal ring, and the combined transdermal patch. The guideline was developed with a team of international experts and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings, and can also be used by women using CHC. Download the document here.
2020 Stakeholder Consultation - PDF
GMC Excellence by Design
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of intrauterine contraception (IUC) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. This guideline was updated in September 2019.
This update of the 2010 Contraception for Women Aged Over 40 Years guideline has been developed by the FSRH and brings together evidence and expert opinion on contraception for women aged over 40 years. The guideline was developed with a team of experts in the relevant fields and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings. This guideline was amended in September 2019.
Change of UKMEC category for use of progestogen-only injectable contraception and intrauterine contraception by women at high risk of HIV infection from UKMEC2 to UKMEC1 (September 2019).
